Precipio (NASDAQ:PRPO) (NASDAQ: PRPO) is a specialty diagnostics company focused on improving outcomes for patients with hematologic and oncologic conditions through rapid, accurate laboratory testing and advanced digital pathology. The company’s core services address the complexities of diagnosing blood cancers and related disorders, combining traditional hematopathology techniques with proprietary technologies designed to enhance sensitivity and specificity. Precipio’s platform covers immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH) and molecular assays, enabling clinicians to make informed treatment decisions sooner.
Central to Precipio’s offering is its suite of branded products and technologies, which include automated slide-preparation systems and AI-driven digital pathology tools. These solutions streamline laboratory workflows and support remote consultations, allowing for faster turnaround times. The company also develops specialized reagent kits for immunophenotyping and molecular profiling, which have been integrated into its CLIA-accredited, CAP-accredited laboratories to ensure consistency and compliance with regulatory standards.
Precipio operates multiple U.S.-based laboratories in strategically selected regions, serving community hospitals, academic medical centers and contract research organizations. Through a network of logistics partnerships, the company provides sample collection and shipping services across North America, Europe and parts of Asia, facilitating global access to its diagnostics capabilities. Strategic collaborations with clinical trial sponsors further extend Precipio’s reach into oncology research, offering companion diagnostics and central laboratory services for novel therapeutics.
Founded in the late 2000s and rebranded to Precipio when it went public, the company has been led by CEO Dominic Sciabica, whose background spans over two decades in medical device innovation and commercial leadership. Under his stewardship, Precipio has expanded its technology portfolio and enhanced its digital infrastructure, positioning the company at the intersection of precision medicine and laboratory diagnostics. The management team’s combined expertise in pathology, bioinformatics and regulatory affairs underpins Precipio’s mission to transform hematologic diagnostics worldwide.
